CPI and Cambridge Design Partnership announce global partnership

CPI and the Cambridge Design Partnership have announced a global partnership which aims to maximise the potential of next-generation diagnostic and healthcare technologies.

CPI is an independent deep-tech innovation centre and founding member of the High Value Manufacturing Catapult and helps drive organisations through their innovation journey, bringing academia, businesses and investors together. It does this by connecting organisations to a bespoke team of experts, specialised innovation development facilities, funding support and innovation tools.

Cambridge Design Partnership delivers end-to-end product and technology development for clients in the healthcare, consumer and industrial equipment sectors. Its work starts at the point a business decides on the need for innovation within a market area and finishes with the launch of a new product or service.

The partnership is intended to build on these capabilities with Cambridge Design Partnership gaining access to CPI’s specialist expertise and capabilities in development and business scale-up which will help to accelerate innovative client projects to market-seeding volumes.

Projects at CPI will benefit from its GMP and ISO13485 certified Quality Management System, ensuring compliance with relevant legislation and standards. CPI specialises in emergent disciplines such as flexible and hybrid electronics, photonics, biotechnology, advanced materials, and formulation providing game-changing innovation to markets with world-changing potential, such as diagnostics and therapeutic medicines.

CPI will secure access to Cambridge Design Partnership’s expertise in a number of technologies such as molecular diagnostics, synthetic biology, and advanced therapies. Cambridge Design Partnership will also provide expert guidance in strategy, planning, product development, manufacture and due diligence as CPI links the UK’s science and research base with supply and value chains.

The partnership’s success will be measured in terms of commercial and patient impact and both plan to shape early-stage innovation into investment-ready business cases and market-ready products. A particular goal is to maximise the impact of the UK’s scientific and technology research base, improving the path to commercialisation and the clinic.

Commenting on the partnership, Cambridge Design Partnership’s Senior Innovation Consultant Pari Datta said, “The UK has a strong science and technology base, with a history of scientific firsts behind many great products now on the global stage. But we don’t always spot the opportunities or navigate the path to commercialisation, particularly in the regulated medical space. With CPI, we’re working to grow the ecosystem which will discover, nurture and scale these promising businesses, leading to great new products delivering real value to patients, professionals and the UK economy.”